{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:58:47Z","timestamp":1787626727682,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11060-026-05468-9","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T10:28:25Z","timestamp":1775298505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Magnetic resonance imaging-based biodistribution of theranostic AGuIX nanoparticles in the NANORAD 2 clinical trial for brain metastases"],"prefix":"10.1007","volume":"177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3417-1313","authenticated-orcid":false,"given":"Fabien","family":"Boux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Talba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Dufort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalide","family":"Seddik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Grand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Gataleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Leboucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Pietras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"De Beaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Le Duc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Verry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"5468_CR1","doi-asserted-by":"publisher","unstructured":"Keall PJ et al (2022) Integrated MRI-guided radiotherapy \u2014 opportunities and challenges. https:\/\/doi.org\/10.1038\/s41571-022-00631-3","DOI":"10.1038\/s41571-022-00631-3"},{"key":"5468_CR2","doi-asserted-by":"publisher","unstructured":"Xie J, Gong L, Zhu S, Yong Y, Gu Z, Zhao Y (Jan. 18 2019) Emerging strategies of nanomaterial-mediated tumor radiosensitization, Wiley-VCH Verlag. https:\/\/doi.org\/10.1002\/adma.201802244","DOI":"10.1002\/adma.201802244"},{"key":"5468_CR3","doi-asserted-by":"publisher","unstructured":"Unkelbach J et al (2018) Robust radiotherapy planning. Phys Med Biol 63(22). https:\/\/doi.org\/10.1088\/1361-6560\/aae659","DOI":"10.1088\/1361-6560\/aae659"},{"key":"5468_CR4","doi-asserted-by":"publisher","unstructured":"Gong L, Zhang Y, Liu C, Zhang M, Han S (2021) Application of radiosensitizers in cancer radiotherapy. https:\/\/doi.org\/10.2147\/IJN.S290438","DOI":"10.2147\/IJN.S290438"},{"key":"5468_CR5","doi-asserted-by":"publisher","DOI":"10.7150\/thno.22172","author":"Y Liu","year":"2018","unstructured":"Liu Y et al (2018) Metal-based nanoenhancers for future radiotherapy: radiosensitizing and synergistic effects on tumor cells. Ivyspring Int Publisher. https:\/\/doi.org\/10.7150\/thno.22172","journal-title":"Ivyspring Int Publisher"},{"key":"5468_CR6","doi-asserted-by":"publisher","unstructured":"Penninckx S, Thariat J, Mirjolet C (2023) Radiation therapy-activated nanoparticle and immunotherapy: the next milestone in oncology? Int Rev Cell Mol Biology 378. https:\/\/doi.org\/10.1016\/bs.ircmb.2023.03.005","DOI":"10.1016\/bs.ircmb.2023.03.005"},{"key":"5468_CR7","doi-asserted-by":"crossref","unstructured":"Guerra DB, Oliveira EM, Sonntag AR (2022) Intercomparison of radiosensitization induced by gold and iron oxide nanoparticles in human glioblastoma cells irradiated by 6 MV photons. Scientific Reports 12(1):9602","DOI":"10.1038\/s41598-022-13368-x"},{"key":"5468_CR8","doi-asserted-by":"publisher","unstructured":"Hainfeld JF, Slatkin DN, Smilowitz HM (2004) The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 49(18). https:\/\/doi.org\/10.1088\/0031-9155\/49\/18\/N03","DOI":"10.1088\/0031-9155\/49\/18\/N03"},{"key":"5468_CR9","doi-asserted-by":"publisher","unstructured":"Bonvalot S et al (2017) First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas. Clin Cancer Res 23(4). https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1297","DOI":"10.1158\/1078-0432.CCR-16-1297"},{"key":"5468_CR10","doi-asserted-by":"publisher","unstructured":"Verry C et al (2020) Targeting brain metastases with ultrasmall theranostic nanoparticles, a first-in-human trial from an MRI perspective. Sci Adv 6(29). https:\/\/doi.org\/10.1126\/sciadv.aay5279","DOI":"10.1126\/sciadv.aay5279"},{"key":"5468_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.radonc.2021.04.021","volume":"160","author":"C Verry","year":"2021","unstructured":"Verry C et al (2021) Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial). Radiother Oncol 160:159\u2013165. https:\/\/doi.org\/10.1016\/j.radonc.2021.04.021","journal-title":"Radiother Oncol"},{"key":"5468_CR12","doi-asserted-by":"publisher","unstructured":"Biau J et al (Sep. 2024) NANO-GBM trial of AGuIX nanoparticles with radiotherapy and Temozolomide in the treatment of newly diagnosed glioblastoma: phase 1b outcomes and MRI-based biodistribution. Clin Transl Radiat Oncol 48:100833. https:\/\/doi.org\/10.1016\/j.ctro.2024.100833","DOI":"10.1016\/j.ctro.2024.100833"},{"key":"5468_CR13","doi-asserted-by":"publisher","unstructured":"Garcia-Prada CD et al (2023) Gadolinium-Based nanoparticles sensitize ovarian peritoneal carcinomatosis to targeted radionuclide therapy. J Nucl Med 64(12). https:\/\/doi.org\/10.2967\/jnumed.123.265418","DOI":"10.2967\/jnumed.123.265418"},{"key":"5468_CR14","doi-asserted-by":"crossref","unstructured":"Maury P, Mondini M, Chargari C, Darricau A, Shahin M, Ammari S, Porcel E (2023) Clinical transfer of AGuIX\u00ae-based radiation treatments for locally advanced cervical cancer: MR quantification and in vitro insights in the NANOCOL clinical trial framework. Nanomed: Nanotechnol, Biol Med 50:102676","DOI":"10.1016\/j.nano.2023.102676"},{"key":"5468_CR15","doi-asserted-by":"publisher","unstructured":"Bennett S et al (Dec. 2024) Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging. Sci Rep 14(1). https:\/\/doi.org\/10.1038\/s41598-024-62389-1","DOI":"10.1038\/s41598-024-62389-1"},{"issue":"1093","key":"5468_CR16","first-page":"20180365","volume":"92","author":"F Lux","year":"2019","unstructured":"Lux F, Tran VL, Thomas E (2019) AGuIX\u00ae from bench to bedside\u2014Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. Br J Radiol 92(1093):20180365","journal-title":"Br J Radiol"},{"issue":"1","key":"5468_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/brain\/113.1.27","volume":"113","author":"KL Leenders","year":"1990","unstructured":"Leenders KL, Perani D, Lammertsma AA (1990) Cerebral blood flow, blood volume and oxygen utilization: normal values and effect of age. Brain 113(1):27\u201347","journal-title":"Brain"},{"issue":"3","key":"5468_CR18","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1021\/acsnano.5b00552","volume":"9","author":"L Sancey","year":"2015","unstructured":"Sancey L, Kotb S, Truillet C (2015) Long-term in vivo clearance of gadolinium-based AGuIX nanoparticles and their biocompatibility after systemic injection. ACS Nano 9(3):2477\u20132488","journal-title":"ACS Nano"},{"key":"5468_CR19","doi-asserted-by":"publisher","unstructured":"Shi Y, van der Meel R, Chen X, Lammers T (2020) The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. https:\/\/doi.org\/10.7150\/thno.49577","DOI":"10.7150\/thno.49577"},{"issue":"4","key":"5468_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/ph18040519","volume":"18","author":"C Aubrun","year":"2025","unstructured":"Aubrun C, Doussineau T, Carm\u00e8s L (2025) Mechanisms of action of AGuIX as a pan-cancer nano-radiosensitizer: a comprehensive review. Pharmaceuticals 18(4):519","journal-title":"Pharmaceuticals"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05468-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05468-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05468-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:15:40Z","timestamp":1778224540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05468-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["5468"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05468-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8401098\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki (as amended in 2013 in Fortaleza). Approval was granted by the Comit\u00e9 de Protection des Personnes (CPP) and the National Agency for Safety of Drugs and Health Products (ANSM). The study was conducted in strict compliance with the recommendations for Good Clinical Practice (GCP, ICHE6). Clinical trial registration: NCT03818386.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Financial interests: G\u00e9raldine Le Duc, Sandrine Dufort and Camille Verry disclose patent No. PCT\/FR2019\/000124 protecting AGuIX nanoparticles described in this publication. G\u00e9raldine Le Duc, Sandrine Dufort and Olivier de Beaumont own shares in NH TherAguix (Meylan, France), which develops AGuIX nanoparticles. Fabien Boux, Daniela Talba, Sandrine Dufort, Khalide Seddik, Olivier de Beaumont and G\u00e9raldine Le Duc are employees at NH TherAguix. The remaining authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}